AI SummaryThis article discusses the discovery and optimization of a series of vinyl sulfoximine-based analogues as potent Nrf2 activators for the treatment of multiple sclerosis. The research focuses on developing new molecules that can activate Nrf2, a protein that plays a key role in protecting cells from oxidative stress and inflammation. The goal is to… Continue reading [ASAP] Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
Tag: Multiple Sclerosis
Ofatumumab MS Study Supports Early Start Over Switch
AI SummaryThis article discusses a study supporting the idea that starting treatment with the more potent drug, ofatumumab, early on in multiple sclerosis patients can reduce the risk of long-term disability accumulation. This suggests that early initiation of treatment with ofatumumab may be more beneficial than switching to it later on.The likelihood of long-term accumulation… Continue reading Ofatumumab MS Study Supports Early Start Over Switch
Positive Stem Cell Transplant Data Are Increasing Its Use
As a rescue intervention for multiple sclerosis (MS), hematopoietic stem cell transplant (HSCT) is being offered with greater frequency. MDedge News
Novel Agent First to Slow Disability in nrSPMS
AI SummaryThis article discusses the effectiveness of the Bruton’s tyrosine kinase inhibitor tolebrutinib in slowing down disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). Tolebrutinib is considered a novel agent that has shown benefits in this patient population.The Bruton’s tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in… Continue reading Novel Agent First to Slow Disability in nrSPMS
[Comment] Evobrutinib in multiple sclerosis: challenges and unmet goals
Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these therapies are less effective at preventing progression independent of relapse activity (PIRA), which can occur at any stage of the disease and is strongly associated with a higher risk of long-term permanent disability.1… Continue reading [Comment] Evobrutinib in multiple sclerosis: challenges and unmet goals
[Articles] Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
The efficacy of evobrutinib was not superior to that of teriflunomide. Together, efficacy and liver-related safety findings do not support the use of evobrutinib in people with relapsing multiple sclerosis.
[In Context] Non-inferiority design for trials in multiple sclerosis
AI SummaryThe article discusses the use of non-inferiority design in trials for comparing new drugs with existing standards in the context of multiple sclerosis. Non-inferiority trials aim to show that a new drug is at least as effective as the existing one, with potential benefits such as fewer side effects or easier administration. This design… Continue reading [In Context] Non-inferiority design for trials in multiple sclerosis
[Personal View] Differential diagnosis of suspected multiple sclerosis: global health considerations
AI SummaryThis article discusses the challenges of differential diagnosis of multiple sclerosis in regions such as Latin America, Africa, the Middle East, eastern Europe, southeast Asia, and the Western Pacific. It highlights how environmental factors, genetic background, and access to medical care vary in these areas compared to North America and western Europe where multiple… Continue reading [Personal View] Differential diagnosis of suspected multiple sclerosis: global health considerations
[Personal View] Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia
AI SummaryThis article discusses the challenges in diagnosing multiple sclerosis among individuals from minority ethnic and racial backgrounds in regions like North America, northern Europe, and Australasia, where diagnostic criteria have been primarily based on data from White populations. It emphasizes the importance of considering social determinants of health and understanding the unique clinical characteristics… Continue reading [Personal View] Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia
[Comment] Diagnosis of multiple sclerosis: challenges and opportunities
AI SummaryThe text discusses the challenges faced in diagnosing multiple sclerosis, especially in regions with limited healthcare resources like low-income and middle-income countries. It highlights the lack of data on multiple sclerosis-related morbidity and mortality in certain regions, making it difficult to predict the global burden of the disease. The article suggests that improving access… Continue reading [Comment] Diagnosis of multiple sclerosis: challenges and opportunities